Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Acadia participates in a conference call hosted by Cowen » 09:25
07/01/20
07/01
09:25
07/01/20
09:25
ACAD

Acadia

$48.47 /

+0.275 (+0.57%)

Cowen Biotech Analyst…

Cowen Biotech Analyst Baral holds a conference call with management on July 1 at 10 am.

ShowHide Related Items >><<
ACAD Acadia
$48.47 /

+0.275 (+0.57%)

ACAD Acadia
$48.47 /

+0.275 (+0.57%)

06/24/20 Citi
Acadia risk/reward skewed to upside into depression data, says Citi
06/23/20 Jefferies
Jefferies sees high odds of positive MDD data from Acadia next month
05/27/20 Oppenheimer
Acadia price target raised to $53 from $48 at Oppenheimer
04/16/20
Fly Intel: Top five analyst initiations
ACAD Acadia
$48.47 /

+0.275 (+0.57%)

  • 18
    Sep
ACAD Acadia
$48.47 /

+0.275 (+0.57%)

ACAD Acadia
$48.47 /

+0.275 (+0.57%)

Over a week ago
Conference/Events
Acadia participates in a conference call hosted by Cowen » 09:08
06/26/20
06/26
09:08
06/26/20
09:08
ACAD

Acadia

$50.27 /

-1.72 (-3.31%)

Cowen Biotech Analyst…

Cowen Biotech Analyst Baral holds a conference call with management on July 1 at 10 am.

ShowHide Related Items >><<
ACAD Acadia
$50.27 /

-1.72 (-3.31%)

ACAD Acadia
$50.27 /

-1.72 (-3.31%)

06/24/20 Citi
Acadia risk/reward skewed to upside into depression data, says Citi
06/23/20 Jefferies
Jefferies sees high odds of positive MDD data from Acadia next month
05/27/20 Oppenheimer
Acadia price target raised to $53 from $48 at Oppenheimer
04/16/20
Fly Intel: Top five analyst initiations
ACAD Acadia
$50.27 /

-1.72 (-3.31%)

  • 18
    Sep
ACAD Acadia
$50.27 /

-1.72 (-3.31%)

ACAD Acadia
$50.27 /

-1.72 (-3.31%)

Recommendations
Acadia risk/reward skewed to upside into depression data, says Citi » 06:28
06/24/20
06/24
06:28
06/24/20
06:28
ACAD

Acadia

$52.76 /

+0.41 (+0.78%)

Citi analyst Neena…

Citi analyst Neena Bitritto-Garg says the risk/reward on shares of Acadia Pharmaceuticals is skewed to the upside into the upcoming CLARITY-2/-3 combined data readout, which she expects could come at some point in July. Though major depressive disorder is an "inherently risky space," the similar design to the CLARITY-1 Phase 2 study and the "creative solution" of combining data from CLARITY-2 and 3 into a single a priori dataset set the company up as well as possible for success, Bitritto-Garg tells investors in a research note. Further, the analyst sees "relatively limited downside," saying modest weakness on results showing a trend but aren't statistically significant would create an attractive entry point. Bitritto-Garg reiterates Acadia as a top pick with a Buy rating and $69 price target.

ShowHide Related Items >><<
ACAD Acadia
$52.76 /

+0.41 (+0.78%)

ACAD Acadia
$52.76 /

+0.41 (+0.78%)

06/23/20 Jefferies
Jefferies sees high odds of positive MDD data from Acadia next month
05/27/20 Oppenheimer
Acadia price target raised to $53 from $48 at Oppenheimer
04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
ACAD Acadia
$52.76 /

+0.41 (+0.78%)

ACAD Acadia
$52.76 /

+0.41 (+0.78%)

ACAD Acadia
$52.76 /

+0.41 (+0.78%)

Recommendations
Jefferies sees high odds of positive MDD data from Acadia next month » 08:33
06/23/20
06/23
08:33
06/23/20
08:33
ACAD

Acadia

$52.35 /

+0.35 (+0.67%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton estimates a 70% likelihood of a successful outcome when Acadia reports data on pimavanserin as an adjunctive therapy in major depressive disorder, or MDD, in about a month. While main focus of investors continues to be on dementia-related psychosis, or DRP, Howerton notes an uptick in interest in the MDD readout. The analyst, who sees a successful MDD outcome unlocking a $1B opportunity, has a Buy rating and $60 price target on Acadia shares.

ShowHide Related Items >><<
ACAD Acadia
$52.35 /

+0.35 (+0.67%)

ACAD Acadia
$52.35 /

+0.35 (+0.67%)

05/27/20 Oppenheimer
Acadia price target raised to $53 from $48 at Oppenheimer
04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
ACAD Acadia
$52.35 /

+0.35 (+0.67%)

ACAD Acadia
$52.35 /

+0.35 (+0.67%)

ACAD Acadia
$52.35 /

+0.35 (+0.67%)

Hot Stocks
Acadia submits Nuplazid sNDA to FDA » 09:10
06/15/20
06/15
09:10
06/15/20
09:10
ACAD

Acadia

$45.87 /

+0.71 (+1.57%)

Acadia announced that the…

Acadia announced that the company submitted a supplemental new drug application, or sNDA, to the FDA to support a potential new indication for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis, or DRP. The FDA previously granted breakthrough therapy designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP. The sNDA is supported by results from the pivotal Phase 3 HARMONY study, which met its primary endpoint, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo. The sNDA also includes efficacy results from two additional placebo-controlled studies, both of which met their respective primary endpoints: The Phase 2 study in patients with Alzheimer's disease psychosis and the Phase 3 study in patients with Parkinson's disease psychosis. The sNDA includes a large safety and tolerability database from completed and ongoing studies representing over 1500 patients with neurodegenerative disease.

ShowHide Related Items >><<
ACAD Acadia
$45.87 /

+0.71 (+1.57%)

ACAD Acadia
$45.87 /

+0.71 (+1.57%)

05/27/20 Oppenheimer
Acadia price target raised to $53 from $48 at Oppenheimer
04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
ACAD Acadia
$45.87 /

+0.71 (+1.57%)

ACAD Acadia
$45.87 /

+0.71 (+1.57%)

ACAD Acadia
$45.87 /

+0.71 (+1.57%)

Over a month ago
Hot Stocks
Acadia appoints Mark Schneyer as Chief Business Officer » 09:11
05/28/20
05/28
09:11
05/28/20
09:11
ACAD

Acadia

$50.65 /

-0.51 (-1.00%)

Acadia (ACAD) announced…

Acadia (ACAD) announced announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. The company said in a release, "Mr. Schneyer will be responsible for sourcing and executing business development opportunities and serve as a member of the company's Executive Management Committee. Schneyer joins Acadia from Pfizer (PFE), where he most recently was Vice President, Business Development, for the Upjohn division."

ShowHide Related Items >><<
ACAD Acadia
$50.65 /

-0.51 (-1.00%)

ACAD Acadia
$50.65 /

-0.51 (-1.00%)

05/27/20 Oppenheimer
Acadia price target raised to $53 from $48 at Oppenheimer
04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
ACAD Acadia
$50.65 /

-0.51 (-1.00%)

ACAD Acadia
$50.65 /

-0.51 (-1.00%)

ACAD Acadia
$50.65 /

-0.51 (-1.00%)

Recommendations
Acadia price target raised to $53 from $48 at Oppenheimer » 07:33
05/27/20
05/27
07:33
05/27/20
07:33
ACAD

Acadia

$51.16 /

-0.09 (-0.18%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson raised the firm's price target on Acadia to $53 from $48 as he increases Probability of Success in MDD to 65% from 50% based on Phase 2 CLARITY-1 results. The analyst notes that MDD pivotal Phase 3 CLARITY-2 US and CLARITY-3 EU trials will be combined into one pivotal study with topline data expected in Q3. Olson anticipates potential sNDA filing in early-2021 and launch in 2022. He has a Perform rating on the shares.

ShowHide Related Items >><<
ACAD Acadia
$51.16 /

-0.09 (-0.18%)

ACAD Acadia
$51.16 /

-0.09 (-0.18%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
ACAD Acadia
$51.16 /

-0.09 (-0.18%)

ACAD Acadia
$51.16 /

-0.09 (-0.18%)

ACAD Acadia
$51.16 /

-0.09 (-0.18%)

Hot Stocks
Acadia to combine CLARITY-2, CLARITY-3 Phase 3 studies » 09:04
05/26/20
05/26
09:04
05/26/20
09:04
ACAD

Acadia

$51.25 /

-0.32 (-0.62%)

ACADIA Pharmaceuticals…

ACADIA Pharmaceuticals announced that following positive feedback from the FDA, the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating pimavanserin for the adjunctive treatment of major depressive disorder, or MDD, into one study with a pre-specified statistical analysis plan. The company said, "As a result, no new patients will be enrolled in the two identically designed Phase 3 studies, each of which will be concluded with slightly more than 50% enrollment. Top-line results from the combined study are expected in the third quarter of 2020. If positive, the results from the combined study, along with the positive results from the previously announced pivotal CLARITY study, would form the basis for a supplemental new drug application for pimavanserin in the adjunctive treatment of MDD."

ShowHide Related Items >><<
ACAD Acadia
$51.25 /

-0.32 (-0.62%)

ACAD Acadia
$51.25 /

-0.32 (-0.62%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
ACAD Acadia
$51.25 /

-0.32 (-0.62%)

ACAD Acadia
$51.25 /

-0.32 (-0.62%)

ACAD Acadia
$51.25 /

-0.32 (-0.62%)

Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Conference/Events
RBC Capital to hold a virtual conference » 08:45
05/19/20
05/19
08:45
05/19/20
08:45
ADUS

Addus HomeCare

$89.93 /

+5.99 (+7.14%)

, HOOK

Hookipa Pharma

$10.15 /

+0.78 (+8.32%)

, KPTI

Karyopharm

$18.65 /

-0.4 (-2.10%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, ENTA

Enanta

$57.58 /

+2.25 (+4.07%)

, REGN

Regeneron

$559.37 /

-16.71 (-2.90%)

, ARAV

Aravive

$12.58 /

+0.11 (+0.88%)

, IMGN

ImmunoGen

$4.76 /

+0.33 (+7.45%)

, HCA

HCA Healthcare

$105.57 /

+6.83 (+6.92%)

, PFE

Pfizer

$38.08 /

+0.31 (+0.82%)

, BCEL

Atreca

$18.75 /

-0.44 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$116.30 /

+4.79 (+4.30%)

, OVID

Ovid Therapeutics

$4.17 /

+0.09 (+2.21%)

, ACAD

Acadia

$52.07 /

+1.23 (+2.42%)

, BMRN

BioMarin

$95.34 /

+1.595 (+1.70%)

, EHTH

eHealth

$127.03 /

+9.13 (+7.74%)

, EXEL

Exelixis

$25.66 /

-0.07 (-0.27%)

, INO

Inovio

$14.15 /

+0.73 (+5.44%)

, SPRT

Support.com

$1.26 /

+0.06 (+5.00%)

, CYH

Community Health

$3.16 /

+0.435 (+15.99%)

, INCY

Incyte

$96.50 /

+0.37 (+0.38%)

, AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

, EGRX

Eagle Pharmaceuticals

$54.50 /

+1.74 (+3.30%)

, IGMS

IGM Biosciences

$55.41 /

-3.59 (-6.08%)

, AIMT

Aimmune

$17.47 /

+1.1 (+6.72%)

, VRCA

Verrica Pharmaceuticals

$10.73 /

+0.47 (+4.58%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$57.58 /

+2.25 (+4.07%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$559.37 /

-16.71 (-2.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
ARAV Aravive
$12.58 /

+0.11 (+0.88%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$38.08 /

+0.31 (+0.82%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.75 /

-0.44 (-2.29%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$52.07 /

+1.23 (+2.42%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$127.03 /

+9.13 (+7.74%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.15 /

+0.73 (+5.44%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.26 /

+0.06 (+5.00%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.